Skip to main content

Advertisement

SpringerLink
Log in

DIABETIC KIDNEY DISEASE

Potential cardiorenal benefits of efpeglenatide in diabetes

  • News & Views
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Building on previous cardiovascular outcome trials with glucagon-like peptide 1 receptor agonists, the AMPLITUDE-O trial reported significant improvements in major adverse cardiovascular and kidney outcomes with efpeglenatide in type 2 diabetes. A longer-term trial with dose-dependent analysis on kidney outcome components will better define the effects of efpeglenatide in the diabetic kidney.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sposito, A. C., Berwanger, O., de Carvalho, L. S. F. & Saraiva, J. F. K. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. Cardiovas. Diabetol. 17, 157 (2018).

    Article  CAS  Google Scholar 

  2. Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2108269 (2021).

    Article  PubMed  Google Scholar 

  3. Zelniker, T. A. et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139, 2022–2031 (2019).

    Article  CAS  Google Scholar 

  4. Muskiet, M. H. A. et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859–869 (2018).

    Article  CAS  Google Scholar 

  5. Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839–848 (2017).

    Article  CAS  Google Scholar 

  6. Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131–138 (2019).

    Article  CAS  Google Scholar 

  7. Bentley-Lewis, R. et al. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am. Heart J. 169, 631–638 (2015).

    Article  CAS  Google Scholar 

  8. Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).

    Article  CAS  Google Scholar 

  9. van der Aart-van der Beek, A. B. et al. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: a post hoc analysis of the EXSCEL trial. Diabetes Obes. Metab. 22, 2493–2498 (2020).

    Article  Google Scholar 

  10. Bethel, M. A. et al. Renal outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). Diabetes https://doi.org/10.2337/db18-522-P (2018).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes, Central Clinical School, Monash University, Melbourne, Victoria, Australia

    Jacques Ma & Mark E. Cooper

Authors
  1. Jacques Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark E. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark E. Cooper.

Ethics declarations

Competing interests

M.E.C. has previously reviewed grants and has been a member of honorary advisory boards for companies that manufacture GLP1 agonists and other glucose-lowering drugs, including AstraZeneca, Novo Nordisk, Boehringer Ingelheim, MSD, Novartis, Sanofi and Eli Lilly and Company. J.M. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, J., Cooper, M.E. Potential cardiorenal benefits of efpeglenatide in diabetes. Nat Rev Nephrol 17, 708–709 (2021). https://doi.org/10.1038/s41581-021-00475-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-021-00475-7

  • Springer Nature Limited

Search

Navigation